Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
Speaker 2: The Stock Movers Report, your roundup of companies making moves
Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
Speaker 1: Let's take a look at some of the stocks on
Speaker 1: the move today on Paul Sweeney alongside Norm Me, Linda,
Speaker 1: and we're joined by Bloomberg's Lise Mattail. Lisa, what are
Speaker 1: you looking at all right?
Speaker 3: We're starting with Carog, Doctor Pepper, Taker KDP. Their shares
Speaker 3: have been up as much as eight percent, so a
Speaker 3: few things. Sales for the third quarter beat estimates. It
Speaker 3: raised its full year sales outlook to be in that
Speaker 3: high single digit range. US coffee sales, which had trunk
Speaker 3: actually for the ten previous quarters, grew one a half percent.
Speaker 3: The focus, though, is really turning to this acquisition of
Speaker 3: Dutch coffee company JdE Pete. It basically announced that the
Speaker 3: eighteen billion dollar deal back in August, and now it
Speaker 3: says it's raising seven billion dollars from Apollo and KKR
Speaker 3: to help finance that acquisition. Investors are going to like
Speaker 3: that because they had come turns that it was going
Speaker 3: to be taking on too much debt from that, but
Speaker 3: carried Doctor Pepper. They planned to separate their beverage and
Speaker 3: their coffee business by the end of twenty twenty six.
Speaker 3: Wow shares of KDP down about fifteen percent so far
Speaker 3: this year.
Speaker 1: Yeah, I'd like doctor Pepper, but I don't drink it
Speaker 1: that often, so not your go to.
Speaker 3: It's not a good in rotation.
Speaker 1: Once, so all I'll throw it in there.
Speaker 3: See, I'm more on the coffee side of things.
Speaker 1: Doctor Pepper's big in Texas. That's where it's from originally.
Speaker 1: So there you go.
Speaker 3: I did right, So yes, Baby oh from right right.
Speaker 3: So we have Baby Power Company Carters. This is ticker
Speaker 3: cri I. Their shares have been down as much as
Speaker 3: seven percent, and they say basically that tariffs are dragging
Speaker 3: down its earnings. They said they can expect to win
Speaker 3: car a pretax earnings impact from additional tariffs of about
Speaker 3: two hundred million to two hundred and fifty million dollars
Speaker 3: a year. They said their full year guidance would also
Speaker 3: main suspended. But here's like the bigger news when you
Speaker 3: look into it. It said it's going to close about one
Speaker 3: hundred and fifty stores in North America after their lease
Speaker 3: is expire of the next three years, and that's up
Speaker 3: from a previous target of one hundred stores. They also
Speaker 3: plan to reduce their office workforce by about fifteen percent.
Speaker 3: We're hearing that a lot from companies, cutting about three
Speaker 3: hundred positions, and they expect that reduction to create about
Speaker 3: thirty five million dollars in annual savings starting next year.
Speaker 3: So that's some big news from Carters.
Speaker 1: I mean, that's I can't imagine. That's what we won
Speaker 1: for our American businesses. This company's based in Atlanta, Georgia.
Speaker 1: Is that the effect of Terrace that we want on.
Speaker 3: I haven't seen Carters in a while. Well, yeah, I've
Speaker 3: seen a lot of their stores. Clothing. I know, it's
Speaker 3: interesting thing, but it's still it's still out there and
Speaker 3: we haven't talked about it much. But yeah, their shares
Speaker 3: have been taking a hit two permit, so we go
Speaker 3: from children's clothing to let's go to pharma. We have
Speaker 3: a video Avidity Biosciences. It's Sticker r n A and
Speaker 3: their shore. It's really their shares have been storing as
Speaker 3: much as forty three percent. So the news behind it
Speaker 3: is that you have Swiss drug maker Novartis. They've agreed
Speaker 3: to buy the company. It's a twelve billion dollar deal.
Speaker 3: You like the mergers. It's Novartis's biggest acquisition in more
Speaker 3: than a decade, so it's big news for them. It's
Speaker 3: also adding several potential treatment starts portfolio because Novartis it's
Speaker 3: facing a lot of competition from those cheap generics later
Speaker 3: this year, especially for its three key drugs that's like
Speaker 3: it's heart medicine includes as well, so Avidity. They're developing
Speaker 3: experimental drugs to treat diseases including neuromuscular illness. But Novarta
Speaker 3: says two to three Avidity drugs they're expected to launch
Speaker 3: before twenty thirty. They say they have a multi billion
Speaker 3: dollar sales potential, so they really see a lot in
Speaker 3: this company. And then as part of this deal, a
Speaker 3: Vidy's going to separate its early stage cardiology programs into
Speaker 3: a new company and some of all of that which
Speaker 3: a Vidy can sell to a third party. So there's
Speaker 3: kind of a lot behind this. But I mean, you
Speaker 3: just heard a lot of biotech m and a's like
Speaker 3: from large for companies buying smaller drug makers, you know,
Speaker 3: with this innovative technology so they can help them like
Speaker 3: boost their revenue. You know, older drugs are losing those
Speaker 3: patent protection and that's the real issue.
Speaker 2: Here the stock Moover's report from Bloomberg Radio. Check back
Speaker 2: with us throughout the day for the latest roundup of
Speaker 2: companies making news on Wall Street and for the latest
Speaker 2: market moving headlines. Listen to Bloomberg Radio Live, catch us
Speaker 2: on YouTube, Bloomberg dot com, and on Applecarplay and Android
Speaker 2: Auto with the Bloomberg Business app.